Author/Authors :
Zhang, Yue-Hua Department of Oncology - Huaihe Hospital of Henan University, Kaifeng, China , Lu, Yuquan International Joint Research Laboratory for Cell Medical Engineering of Henan - Huaihe Hospital of Henan University, Kaifeng, China , Lu, Hong Department of Oncology - Huaihe Hospital of Henan University, Kaifeng, China , Zhang, Meng-Wei Department of Oncology - Huaihe Hospital of Henan University, Kaifeng, China , Zhou, Yue-Min International Joint Research Laboratory for Cell Medical Engineering of Henan - Huaihe Hospital of Henan University, Kaifeng, China , Li, Xiang-Lei Department of Oncology - Huaihe Hospital of Henan University, Kaifeng, China
Abstract :
Background/Aim. Few studies have reported the prognostic value of pretreatment hemoglobin levels in patients with lung adenocarcinoma (LA). In the present study, we retrospectively reviewed 306 LA patients for their prognosis associated with the pretreatment
hemoglobin levels. Methods. Person-years and case fatality rate (CFR) were calculated from May 2010 to June 2017. Hazard ratio (HR)
and 95% confidence intervals (CIs) were estimated using the Cox proportional hazards regression analysis. Survival curves were
generated using the Kaplan–Meier analysis. Results. Patients with low pretreatment hemoglobin (LPHb) levels had a higher CFR than
did patients with normal pretreatment hemoglobin (NPHb) levels (HR= 1.48, 95% CI = 1.06–2.08, and P = 0.023). Overall survival of
NPHb patients was significantly higher than that of LPHb patients (P < 0.05). Conclusion. Low pretreatment hemoglobin level was
demonstrated to be an independent biomarker for poor prognosis in patients with LA.
